Skip to Content

DexCom Inc DXCM

Morningstar Rating
$129.98 −4.28 (3.19%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Dexcom Poised for Further Adoption of G7

Dexcom enjoys a well-established track record for introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an impressive slice of this CGM market, but a recent wave of innovation in the diabetes device market has intensified competitive pressure. Nonetheless, Dexcom has done a credible job of adapting and fending off competition from Abbott and Medtronic.

Price vs Fair Value

DXCM is trading within a range we consider fairly valued.
Price
$134.30
Fair Value
$915.00
Uncertainty
High
1-Star Price
$316.62
5-Star Price
$33.00
Economic Moat
Nltc
Capital Allocation
Vllcslzqcx

Bulls Say, Bears Say

Bulls

Dexcom's next-gen G7 product should be significantly less expensive, offer a thinner profile, and faster warm-up time than G6.

Bears

Considering Dexcom's sensors are already the most accurate, there's less opportunity for significant improvements on that dimension, compared with key competitors.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DXCM is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$134.26
Day Range
$129.55134.81
52-Week Range
$74.80141.70
Bid/Ask
$129.92 / $130.04
Market Cap
$50.09 Bil
Volume/Avg
1.4 Mil / 3.1 Mil

Key Statistics

Price/Earnings (Normalized)
90.46
Price/Sales
16.04
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
1.28%

Company Profile

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Growth
Total Number of Employees
9,600

Competitors

Valuation

Metric
DXCM
MDT
ABT
Price/Earnings (Normalized)
90.4614.6423.71
Price/Book Value
25.432.034.73
Price/Sales
16.043.264.56
Price/Cash Flow
77.9414.4218.91
Price/Earnings
DXCM
MDT
ABT

Financial Strength

Metric
DXCM
MDT
ABT
Quick Ratio
2.391.461.16
Current Ratio
2.842.301.64
Interest Coverage
29.348.8610.86
Quick Ratio
DXCM
MDT
ABT

Profitability

Metric
DXCM
MDT
ABT
Return on Assets (Normalized)
10.03%7.75%10.63%
Return on Equity (Normalized)
28.40%13.75%20.87%
Return on Invested Capital (Normalized)
11.06%9.87%14.81%
Return on Assets
DXCM
MDT
ABT
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesJxjcyzlvJlcfppk$182.7 Bil
SYK
Stryker CorpPrvrtrptMqzv$124.6 Bil
MDT
Medtronic PLCLxznwlmGwgvcd$105.2 Bil
BSX
Boston Scientific CorpPhfdfgngYyhbdsx$99.1 Bil
EW
Edwards Lifesciences CorpKzrtqpzmxWpqqgg$52.0 Bil
ZBH
Zimmer Biomet Holdings IncTryhgzpwdKsvgc$24.5 Bil
ALGN
Align Technology IncRrvpzwrcZhxmk$22.7 Bil
PHG
Koninklijke Philips NV ADRRtzkgdyyXfpvxk$18.3 Bil
PODD
Insulet CorpLrngsvdnfYmhtp$11.6 Bil

Sponsor Center